Basilea Pharmaceutica (XSWX:BSLN) Short-Term Debt: CHF0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
58 GF Score
Price CHF51.80
GF Value CHF57.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Short-Term Debt?

Basilea Pharmaceutica XSWX:BSLN 58 Short-Term Debt is CHF0.0 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 58/100 and a GF Value™ of CHF57.80 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Basilea Pharmaceutica's Short-Term Debt for the quarter that ended in Dec. 2025 was CHF0.0 Mil.

Basilea Pharmaceutica's annual Short-Term Debt declined from Dec. 2023 (CHF15.5 Mil) to Dec. 2024 (CHF0.0 Mil) but then stayed the same from Dec. 2024 (CHF0.0 Mil) to Dec. 2025 (CHF0.0 Mil).

Basilea Pharmaceutica Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Basilea Pharmaceutica Short-Term Debt Related Terms

Basilea Pharmaceutica Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Short-Term Debt Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.51 37.47 15.45 0.00 0.00

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.45 0.00 0.00 0.00 0.00
XSWX:BSLN
58GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of CHF0.0 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Short-Term Debt of CHF0.0 Mil as of Dec. 2025.
Is Basilea Pharmaceutica's Short-Term Debt too high?
Basilea Pharmaceutica's current Short-Term Debt is CHF0.0 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Short-Term Debt compare to VRTX and REGN?
Basilea Pharmaceutica's Short-Term Debt of CHF0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Basilea Pharmaceutica's current Short-Term Debt is CHF0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.80, compared to a current price of CHF51.80 — trading 10.4% below its estimated fair value. The current Short-Term Debt is CHF0.0 Mil. Basilea Pharmaceutica's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Short-Term Debt is CHF0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF51.80 is trading 10.4% below its estimated GF Value™ of CHF57.80. GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.

Key valuation signals for XSWX:BSLN:

  • Short-Term Debt: CHF0.0 Mil
  • GF Value™: CHF57.80 vs. price of CHF51.80 (10.4% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
58GF Score

Get the complete analysis for XSWX:BSLN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.80
Price
CHF57.80
GF Value